

**August 13, 2024**

National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex  
Bandra (E), Mumbai-400051

BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

**Ref: Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Sub: Investors Presentation Q1-F.Y. 2024-25 – Orchid Pharma Limited ("the Company")**

Dear Sir/Madam,

With reference to the captioned subject and pursuant to Regulation 30 read with Schedule III Part A Para A Sub- Para 15 of SEBI (Listing Obligation and Disclosures Requirement) Regulations, 2015, as amended, and in continuation to our earlier intimation dated August 07, 2024 regarding the Analyst/Investors Earning Call scheduled to be held on August 13, 2024 at 04:00 P.M. (IST), please find enclosed the Investors Presentation, inter-alia, including the financial performance of the Company for the Quarter-1 of Financial Year 2024-25, ended on June 30, 2024.

The Investor Presentation is also made available on the website of the Company at [www.orchidpharma.com](http://www.orchidpharma.com).

You are requested to take the above intimation on record.

Thanking You,  
For **Orchid Pharma Limited**

**Kapil Dayya**  
**Company Secretary & Compliance Officer**

***Encl. as above***

# Orchid Pharma Limited

## Financials Q1 & FY 2024-25

- All results in Standalone basis.
- These are approx. nos. for exact nos. pls refer financials.

# Financial Highlights

QTR-1

FY 23-24



Top line

34%

23%

EBIDTA

71%

37%

PBT

169%

472%

PAT


169%

72%


# Financial Performance Summary

(Rs/Crore)	Q1-2025	Q1-2024	Change %	12M-31 <sup>st</sup> Mar'24
Sales	244.4	182.9	+34%	819.4
Other Income	7.8	1.9		30.4
COGS	150.3	112.1		484.6
Employee Exp	21.4	16.2		69.6
Other Exp	39.5	32.5		154.6
EBITDA	41.0	24.0	+71%	141.0
% to Sales	17%	13%		17%
Interest	3.5	5.5	-36%	16.3
Depreciation	8.4	7.7	+9%	33.2
PBT	29.1	10.8		91.5
PAT	29.1	10.8		94.7

# Turnover (In Cr.)




# EBIDTA, PBT & PAT as % to Sales Q1-25




# P&L Analysis – Gross Margin % to Sales

Gross Margin for Quarterly



# P&L Analysis – Exp. % to Sales Q1-25



Thank You